In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine
about
Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir.Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.Topical microbicides and HIV prevention in the female genital tractThe emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV preventionSubtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptaseEffect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues.Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase.The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug ResistanceThe connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South AfricaVaginal microbicides and their delivery platforms.Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398.Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity.In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection.Facile synthesis of the NNRTI microbicide MC-1220 and synthesis of its phosphoramidate prodrugs.
P2860
Q33598736-0D1977BA-ADBE-451C-A985-828D63CCB637Q33624190-24A9C0FD-CD34-4C45-B8B9-62925AE93843Q34058254-6AE45D7E-A08D-4A97-9ED3-DA2A032DE052Q34086820-461A0A70-3C30-4F09-9995-A8BB74654912Q34102246-09331C13-E0B3-498E-84E4-E54751AF97FCQ35002085-E67D7C5B-F5EB-4878-A577-13757299AF0CQ35607740-74BB3E5F-5D79-497B-8C71-21FC7C88353CQ36276790-359F90FB-042F-40F2-8EF7-6E1F2D12A5D6Q36292765-34F955F0-2635-4D34-ABCC-793EE08FD654Q36397384-D14E7361-4BD7-45FF-BF75-FB3BD79453BEQ36969977-877E28E5-76BA-4BA7-A404-2317A9FA3A66Q37253552-7B1B0941-16D7-4481-9F94-A7423E4CE646Q37263786-3BD2BD42-C44A-4131-910E-9BA347AC5E32Q37288671-A6AEBE62-4702-4531-AF86-0E0419548A29Q37547275-9E0A01DC-63FA-4338-B2E5-750696CF6672Q37613017-512A6477-0422-437C-9275-4369CD7C5F82Q38186138-D631CCC7-0C31-481D-A087-B38E258936B9Q38879629-A18F42C5-3CD7-4DF6-B94E-DD5C5E0E1D48Q39124126-312155F2-A07E-48C9-8E46-56631BAEF544Q40200460-70A7620F-D179-4184-9A86-38A420F0893BQ41095817-6BD350D6-1118-40AE-88E4-A23AB7DC23F6
P2860
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine
@ast
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine
@en
type
label
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine
@ast
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine
@en
prefLabel
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine
@ast
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine
@en
P2093
P2860
P356
P1476
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine
@en
P2093
Daniela Moisi
Mark A Wainberg
Maureen Oliveira
Ruxandra-Ilinca Ibanescu
Susan M Schader
Susan P Colby-Germinario
P2860
P304
P356
10.1128/AAC.05821-11
P407
P577
2011-11-28T00:00:00Z